1. Generics Bulletin
  2. >>Business
  3. >>Deals

Another US Stelara Settlement Arrives, This Time For Fresenius And Formycon

Deal With Johnson & Johnson Allows US Biosimilar Ustekinumab Entry In 2025

 
• By Dave Wallace

A third settlement has been struck allowing a Stelara biosimilar to hit the US market in 2025, with partners Fresenius and Formycon agreeing terms with Johnson & Johnson that offer a launch date slightly later than previous settlers.

Red jigsaw pieces spelling out '2025'
The pieces are starting to fall into place for a series of ustekinumab biosimilar launches in the US in 2025 • Source: Shutterstock

With news of a third settlement over a proposed Stelara (ustekinumab) biosimilar in the US, a pattern seems to be emerging: the earlier you settle with Johnson & Johnson, the earlier your rival to Stelara can hit the market.

Fresenius Kabi and Formycon have just announced a settlement over their partnered FYB202 candidate with the originator, with terms that offer the partners a US launch date “no later than 15

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.